HIV 진단약 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별(항체 검사, 바이러스 부하 검사, CD4 검사, 기타), 모드별, 최종 용도별, 지역별, 경쟁별(2020-2030F)
HIV Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Test Type (Antibody Tests, Viral Load Tests, CD4 Test, Others), By Mode, By End-use, By Region and Competition, 2020-2030F
상품코드:1703282
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 HIV 진단약 시장은 2024년에 45억 3,000만 달러로 평가되고, 2030년에는 74억 7,000만 달러에 달하며, CAGR 8.68%로 성장할 것으로 예측됩니다.
1980년대 초 에이즈가 출현한 이래로 HIV 진단 약품의 상황은 크게 발전해 왔습니다. 진단 기술의 발전, 일반 대중의 인식 개선, 검사에 대한 광범위한 접근성은 모두 HIV/AIDS 전염병에 대한 전 세계 대응에 매우 중요한 역할을 하고 있습니다. 오늘날 HIV 진단약 분야는 역동적이고 빠르게 발전하는 산업으로, 질병 관리 개선과 근절에 대한 새로운 희망을 가져다주고 있습니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
45억 3,000만 달러
시장 규모 : 2030년
74억 7,000만 달러
CAGR : 2025-2030년
8.68%
급성장 부문
항체 검사
최대 시장
북미
HIV(인간면역결핍바이러스)는 감염 방어에 중요한 CD4 세포를 표적으로 삼아 면역체계를 손상시킵니다. 적시에 치료하지 않으면 HIV는 후천성면역결핍증후군(AIDS)으로 진행되어 기회감염과 특정 암에 대한 취약성을 증가시킵니다. 지속적인 노력에도 불구하고 전 세계 HIV/AIDS의 유행은 여전히 시급한 공중보건 문제이며, UNAIDS에 따르면 2019년 현재 약 3,800만 명이 HIV와 함께 살고 있다고 합니다. 감염률과 에이즈 관련 사망률 감소에 진전을 보이고 있지만, 지속적인 과제는 바이러스의 영향을 완화하는 데 있으며, 접근성이 높고 정확한 진단 약품의 중요성을 강조하고 있습니다.
시장 성장 촉진요인
HIV 이환율의 상승이 진단약 수요를 촉진
시장이 해결해야 할 과제
접근성과 인지도 장벽
시장 동향
기술 혁신이 시장 확대를 촉진
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 HIV 진단약 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
제품별(소모품, 기기, 소프트웨어, 서비스)
검사의 유형별(항체 검사(HIV-1 스크리닝 검사, HIV-1 항체 확인 검사, HIV-2 및 그룹 O 진단 검사), 바이러스 양검사, CD4 검사, 기타)
모드별(셀프 테스트, 실험실 기반)
최종 용도별(진단 검사실, 병원·진료소, 가정)
기업별(2024)
지역별
시장 맵
제6장 북미의 HIV 진단약 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 HIV 진단약 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 HIV 진단약 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 HIV 진단약 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 HIV 진단약 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병과 인수
제품 출시
최근 동향
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Thermo Fisher Scientific, Inc.
Alere Inc.
Abbott Laboratories inc.
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Gilead Sciences, Inc.
Merck & Co. Inc.
VIIV Healthcare
Beckman Coulter, Inc.
Sysmex Europe SE
Zyomtronix, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
제15장 전략적 제안
제16장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
Global HIV Diagnostics market was valued at USD 4.53 billion in 2024 and is projected to reach USD 7.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.68%. Since the emergence of AIDS in the early 1980s, the HIV diagnostics landscape has evolved significantly. Advances in diagnostic technologies, increased public awareness, and broader access to testing have all played pivotal roles in the global response to the HIV/AIDS epidemic. Today, the HIV diagnostics sector represents a dynamic and rapidly advancing industry, offering renewed hope for improved disease management and, ultimately, eradication.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.53 Billion
Market Size 2030
USD 7.47 Billion
CAGR 2025-2030
8.68%
Fastest Growing Segment
Antibody Tests
Largest Market
North America
HIV (Human Immunodeficiency Virus) compromises the immune system by targeting CD4 cells, critical to defending against infections. Without timely treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), increasing vulnerability to opportunistic infections and certain cancers. Despite ongoing efforts, the global HIV/AIDS epidemic remains a pressing public health concern, with millions affected worldwide. According to UNAIDS, approximately 38 million individuals were living with HIV as of 2019. While progress has been made in reducing infection rates and AIDS-related mortality, persistent challenges underscore the importance of accessible, accurate diagnostics in mitigating the virus's impact.
Market Drivers
Rising HIV Prevalence Fueling Demand for Diagnostics
The growing global prevalence of HIV/AIDS continues to be a major driver of the HIV diagnostics market. As per the World Health Organization (WHO), around 39.9 million people were living with HIV at the end of 2023, with Sub-Saharan Africa remaining the most affected region, accounting for over two-thirds of global cases. However, HIV continues to affect populations worldwide, reinforcing the universal demand for reliable diagnostic solutions.
Despite preventive measures and treatment advancements, the incidence of new HIV infections remains concerning. In 2023 alone, an estimated 1.3 million individuals acquired HIV. Contributing factors include limited access to preventive education, lack of contraceptive availability, and ongoing social stigma, which impedes testing and treatment efforts. The growing global population also means a rise in the absolute number of individuals living with HIV, thereby intensifying the need for early detection and clinical management.
Timely diagnosis is essential for initiating antiretroviral therapy (ART), which improves quality of life and reduces the risk of transmission. Early detection also helps prevent disease progression to AIDS, subsequently lowering mortality rates. In 2023, AIDS-related illnesses claimed approximately 630,000 lives worldwide. As such, the increasing burden of HIV has bolstered the demand for robust diagnostic tools, reinforcing their role in treatment planning, prevention, and public health management.
Market Challenges
Barriers to Accessibility and Awareness
Despite advancements, significant challenges persist, particularly in low- and middle-income countries where healthcare systems often lack the resources necessary for effective HIV diagnosis. In many rural and underserved areas, diagnostic services are limited due to poor infrastructure, inadequate transportation, and a shortage of trained medical personnel. These systemic gaps lead to late diagnoses and delayed treatment initiation.
Even in areas where diagnostic tools are available, factors such as inconsistent electricity supply, inadequate refrigeration for test kits, and substandard sanitary conditions compromise test accuracy. Moreover, social stigma, fear of discrimination, and misinformation continue to deter individuals from seeking testing. Misperceptions about personal risk and reluctance to discuss sexual health further hinder diagnosis efforts. In regions where comprehensive sex education is lacking, knowledge gaps contribute to the continued spread of HIV.
Cultural and language barriers, as well as insufficiently localized public health campaigns, further limit the effectiveness of outreach programs. Bridging these gaps requires a multifaceted strategy, including investment in healthcare infrastructure, community-based awareness initiatives, and integration of HIV testing into routine healthcare services. Closing the accessibility and awareness gap is crucial for improving early detection and reducing global HIV transmission rates.
Market Trends
Technological Innovation Driving Market Expansion
The HIV diagnostics market has been notably influenced by continuous advancements in testing technologies. One of the most transformative developments has been the rise of point-of-care testing (POCT) devices. These portable tools deliver rapid results-often within 30 minutes-enabling immediate clinical action and reducing transmission risks. POCT has been particularly valuable in resource-constrained environments lacking advanced laboratory infrastructure.
Nucleic acid testing (NAT) has further enhanced diagnostic accuracy by detecting the virus's genetic material directly, allowing for earlier identification and minimizing false-negative results. In parallel, next-generation sequencing (NGS) technologies have facilitated deeper understanding of HIV strain diversity, which is vital given the virus's high mutation rate. This knowledge supports the development of more targeted diagnostics and therapies.
Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based platforms, offer improved sensitivity and specificity. These tests can differentiate between HIV-1 and HIV-2 and are less susceptible to false positives.
Key Market Players
Thermo Fisher Scientific, Inc.
Alere Inc.
Abbott Laboratories inc.
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Gilead Sciences, Inc.
Merck & Co. Inc.
VIIV Healthcare
Beckman Coulter, Inc.
Sysmex Europe SE
Zyomtronix, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Report Scope:
In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
HIV Diagnostics Market, By Product:
Consumables
Instruments
Software and Services
HIV Diagnostics Market, By Test Type:
Antibody Tests
Viral Load Tests
CD4 Test
Others
HIV Diagnostics Market, By Mode:
Self-Test
Lab-based
HIV Diagnostics Market, By End-use:
Diagnostic Laboratories
Hospitals & Clinics
Home Settings
HIV Diagnostics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.
Available Customizations:
Global HIV Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global HIV Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Consumables, Instruments, Software and Services)
5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
5.2.3. By Mode (Self-Test, Lab-based)
5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
5.2.5. By Company (2024)
5.2.6. By Region
5.3. Market Map
6. North America HIV Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Test Type
6.2.3. By Mode
6.2.4. By End-use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States HIV Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Test Type
6.3.1.2.3. By Mode
6.3.1.2.4. By End-use
6.3.2. Mexico HIV Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Test Type
6.3.2.2.3. By Mode
6.3.2.2.4. By End-use
6.3.3. Canada HIV Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Test Type
6.3.3.2.3. By Mode
6.3.3.2.4. By End-use
7. Europe HIV Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Test Type
7.2.3. By Mode
7.2.4. By End-use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France HIV Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Test Type
7.3.1.2.3. By Mode
7.3.1.2.4. By End-use
7.3.2. Germany HIV Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Test Type
7.3.2.2.3. By Mode
7.3.2.2.4. By End-use
7.3.3. United Kingdom HIV Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Test Type
7.3.3.2.3. By Mode
7.3.3.2.4. By End-use
7.3.4. Italy HIV Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Test Type
7.3.4.2.3. By Mode
7.3.4.2.4. By End-use
7.3.5. Spain HIV Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Test Type
7.3.5.2.3. By Mode
7.3.5.2.4. By End-use
8. Asia-Pacific HIV Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Test Type
8.2.3. By Mode
8.2.4. By End-use
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China HIV Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Test Type
8.3.1.2.3. By Mode
8.3.1.2.4. By End-use
8.3.2. India HIV Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Test Type
8.3.2.2.3. By Mode
8.3.2.2.4. By End-use
8.3.3. South Korea HIV Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Test Type
8.3.3.2.3. By Mode
8.3.3.2.4. By End-use
8.3.4. Japan HIV Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Test Type
8.3.4.2.3. By Mode
8.3.4.2.4. By End-use
8.3.5. Australia HIV Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Test Type
8.3.5.2.3. By Mode
8.3.5.2.4. By End-use
9. South America HIV Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Test Type
9.2.3. By Mode
9.2.4. By End-use
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil HIV Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Test Type
9.3.1.2.3. By Mode
9.3.1.2.4. By End-use
9.3.2. Argentina HIV Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Test Type
9.3.2.2.3. By Mode
9.3.2.2.4. By End-use
9.3.3. Colombia HIV Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Test Type
9.3.3.2.3. By Mode
9.3.3.2.4. By End-use
10. Middle East and Africa HIV Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Test Type
10.2.3. By Mode
10.2.4. By End-use
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa HIV Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Test Type
10.3.1.2.3. By Mode
10.3.1.2.4. By End-use
10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
